IGC Reports Financial Results for the Quarter Ended June 30, 2022

Rhea-AI Summary

India Globalization Capital (IGC) reported its financial results for Q1 2023 ended June 30, 2022. Revenue increased to approximately $212,000 from $77,000 in Q1 2022. The company has submitted a Phase 2 clinical trial protocol to the FDA for IGC-AD1 aimed at treating agitation in Alzheimer's patients. R&D expenses rose significantly to $1.4 million, a 214% increase due to the trial progress. However, a net loss of $2.8 million, or ($0.05) per share, was recorded, up from a net loss of $1.8 million or ($0.04) per share in the previous year.

Positive

• Revenue increased to approximately $212,000 from $77,000 year-over-year.
• Phase 2 trial protocol for IGC-AD1 submitted to the FDA.
• SG&A expenses decreased to approximately $1.5 million, a 13% reduction.

Negative

• Net loss increased to approximately $2.8 million from $1.8 million year-over-year.
• R&D expenses surged 214% to $1.4 million, indicating higher spending.

POTOMAC, Md.--(BUSINESS WIRE)-- India Globalization Capital, Inc. (“IGC” or the “Company”) (NYSE American: IGC) announces its financial results for the three months ended June 30, 2022, which is the first quarter of the Company’s 2023 fiscal year.

The highlights for the quarter are:

• The Company has submitted a protocol to the U.S. Food and Drug Administration (FDA) titled “A Phase 2, Multi-Center, Double-Blind, Randomized, Placebo-controlled, trial of the safety and efficacy of IGC-AD1 on agitation in participants with dementia due to Alzheimer’s disease.” The protocol is powered at 146 Alzheimer’s patients with half receiving placebo and is a superiority, parallel group study. The primary end point is agitation in dementia due to Alzheimer’s disease as rated by the Cohen-Mansfield Agitation Inventory (CMAI) over a six-week period. The Company has signed agreements with trial sites for conducting the trial, pending FDA approval.
• On June 7, 2022, the USPTO issued a patent (#11,351,152) to the Company titled “Method and Composition for Treating Seizure Disorders.” The patent relates to compositions and methods for treating multiple types of seizure disorders and epilepsy in humans and animals using a combination of the CBD with other compounds. Subject to further research and study, the combination is intended to reduce side effects caused by hydantoin anticonvulsant drugs such as phenobarbital, by reducing the dosing of anticonvulsant drugs in humans, dogs, and cats.
• On May 10, 2022, Hamsa Biopharma India Pvt. Ltd. (“Hamsa Biopharma”), a directly owned subsidiary of the Company, completed outstanding items in the agreement executed with the Jawaharlal Nehru Centre for Advanced Scientific Research (“JNCASR”). The agreement was signed on March 28, 2022, and the Company obtained exclusive global rights to certain molecules, technology, patent, and patent filings.

Revenue was approximately $212 thousand and $77 thousand for the three months ended June 30, 2022, and June 30, 2021, respectively. Revenue in both quarters was primarily derived from our Life Sciences segment, which involved sales of products such as lotion, gummies, and alcohol-based hand sanitizers, among others.

Selling, general, and administrative (“SG&A”) expenses were approximately $1.5 million for the three months ended June 30, 2022, and approximately $1.8 million for the three months ended June 30, 2021, a decrease of approximately $226 thousand or 13% stemming mostly from a decrease in marketing and legal expenses. SG&A expenses consist primarily of employee-related expenses, sales and marketing, professional and legal fees, other corporate expenses, allocated general overhead and provisions, depreciation and write-offs relating to doubtful accounts and advances, if any.

Research and Development (“R&D”) expenses were $1.4 million during the three months ended June 30, 2022, and approximately $444 thousand for the three-month ended June 30, 2021. The increase of approximately $950 thousand or 214% is primarily attributable to the progression of Phase 2 trials on IGC-AD1 and pre-clinical studies on TGR-63. We anticipate additional increases in R&D expenses as the Phase 2 trials on IGC-AD1 commence.

Net loss for the three months ended June 30, 2022, was approximately $2.8 million or ($0.05) per share, compared to approximately $1.8 million or ($0.04) per share for the three months ended June 30, 2021.

About IGC:

IGC has two segments: Life Sciences and Infrastructure. The company is based in Maryland, U.S.A.

Forward-looking Statements: This press release contains forward-looking statements. These forward-looking statements are based largely on IGC’s expectations and are subject to several risks and uncertainties, certain of which are beyond IGC’s control. Actual results could differ materially from these forward-looking statements as a result of, among other factors, the Company’s failure or inability to commercialize one or more of the Company’s products or technologies, including the products or formulations described in this release, or failure to obtain regulatory approval for the products or formulations, where required; general economic conditions that are less favorable than expected, including as a result of the ongoing COVID-19 pandemic; the FDA’s general position regarding cannabis- and hemp-based products; and other factors, many of which are discussed in IGC’s SEC filings. IGC incorporates by reference the human trial disclosures and Risk Factors identified in its Annual Report on Form 10-K filed with the SEC on June 23, 2022, as if fully incorporated and restated herein. In light of these risks and uncertainties, there can be no assurance that the forward-looking information contained in this release will occur.

< Financial Tables to Follow>

India Globalization Capital, Inc.
CONSOLIDATED BALANCE SHEETS
(in thousands, except share data)
(Unaudited)
		June 30, 2022 ($)					March 31, 2022 ($)
ASSETS
Current assets:
Cash and cash equivalents			8,053					10,460
Accounts receivable, net			147					125
Inventory			3,622					3,548
Deposits and advances			905					978
Total current assets			12,727					15,111
Intangible assets, net			937					917
Property, plant and equipment, net			9,161					9,419
Claims and advances			922					937
Operating lease asset			419					450
Total long-term assets			11,439					11,723
Total assets			24,166					26,834
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable			456					981
Accrued liabilities and others			1,200					1,457
Short-term loans			3					3
Total current liabilities			1,659					2,441
Long-term loans			143					144
Other liabilities			16					16
Operating lease liability			308					341
Total non-current liabilities			467					501
Total liabilities			2,126					2,942
Commitments and Contingencies – See Note 12
Stockholders’ equity:
Preferred stock, $0.0001 par value: authorized 1,000,000 shares, no shares issued or outstanding as of June 30, 2022, and March 31, 2022.
Common stock and additional paid-in capital, $0.0001 par value: 150,000,000 shares authorized; 51,840,603 and 51,054,017 shares issued and outstanding as of June 30, 2022 and March 31, 2022, respectively.			117,171					116,019
Accumulated other comprehensive loss			(3,187	)				(2,968	)
Accumulated deficit			(91,944	)				(89,159	)
Total stockholders’ equity			22,040					23,892
Total liabilities and stockholders’ equity			24,166					26,834

These financial statements should be read in connection with the accompanying notes on Form 10-Q for the quarter ended June 30, 2022, filed with the SEC on August 5, 2022.

India Globalization Capital, Inc.
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(in thousands, except loss per share and share data)
(Unaudited)
		Three months ended June 30,
		2022 ($)					2021 ($)
Revenue			212					77
Cost of revenue			(70	)				(51	)
Gross profit			142					26
Selling, general and administrative expenses			(1,550	)				(1,776	)
Research and development expenses			(1,394	)				(444	)
Operating loss			(2,802	)				(2,194	)
Impairment of investment			-					(37	)
Other income, net			17					443
Loss before income taxes			(2,785	)				(1,788	)
Income tax expense/benefit			-					-
Net loss attributable to common stockholders			(2,785	)				(1,788	)
Foreign currency translation adjustments			(219	)				(86	)
Comprehensive loss			(3,004	)				(1,874	)
Loss per share attributable to common stockholders:
Basic & diluted		$	(0.05	)			$	(0.04	)
Weighted-average number of shares used in computing loss per share amounts:			51,616,598					47,910,866

These financial statements should be read in connection with the accompanying notes on Form 10-Q for the quarter ended June 30, 2022, filed with the SEC on August 05, 2022.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220808005223/en/

Claudia Grimaldi

301-983-0998

Source: India Globalization Capital, Inc.

FAQ

What are the financial results of IGC for Q1 2023?

IGC reported revenue of approximately $212,000 and a net loss of approximately $2.8 million for the three months ended June 30, 2022.

What clinical trial protocol did IGC submit to the FDA?

IGC submitted a protocol for a Phase 2 trial of IGC-AD1 aimed at treating agitation in patients with Alzheimer's disease.

How did the SG&A expenses perform for IGC in Q1 2023?

SG&A expenses decreased to approximately $1.5 million, a reduction of about $226,000 or 13% compared to the previous year.

What are the R&D expenses for IGC in Q1 2023?

R&D expenses for IGC were approximately $1.4 million, a significant increase of 214% from the previous year.